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The annual Yale Chemical Biology Symposium took
place on May 12 and sparkled with exciting talks
from scientists representing the breadth of chemical
biology research. The program featured Drs. Laura
Kiessling, Ann Valentine, Chad Mirkin, Ronald Raines,
and Benjamin Turk, with Dr. Christopher Walsh pre-
senting the keynote address. This year’s talks touched
on a variety of topics including stem cells, nano-
science, and the biosynthesis of natural products.
The importance of bioinorganic chemistry and the es-
sential contributions ofmetalloenzymes interlaced the
talks throughout the day.
On Friday, May 12, members of the Yale and northeast-
ern U.S. scientific communities braved torrential rain to
participate in the annual Yale Chemical Biology Sympo-
sium. Although the event did not have a stated theme,
this year’s talks held a distinct bioinorganic flavor while
showcasing a broad spectrum of chemical biology
questions.
The day began with a talk from Dr. Laura Kiessling
from the University of Wisconsin at Madison who de-
scribed the initial stages of her work designing chemical
approaches to controlling cell-fate decisions in embry-
onic stem (ES) cells. Differentiation relies on signaling,
which is often mediated through clustered receptors,
a process promoted by multivalent ligands. Biological
roles for multivalency have been a long-standing inter-
est of the Kiessling lab. Dr. Kiessling described her col-
laboration with Dr. Jamie Thompson to create synthetic
versions of the niches, which are local environments
where stem cells interact with morphogens, other cells,
and the extracellular matrix and that determine how
a stem cell will differentiate. Kiessling’s synthetic niches
are based on alkane thiol self-assembled monolayers
and small-molecule or peptide-based morphogens. In
a pilot assay, members of her group screened for pep-
tides derived from laminin (a major component of Mattri-
gel, a mixture of mouse extracellular matrix proteins cur-
rently essential for culturing ES cells) that could induce
ES cell proliferation on the synthetic surface. A popula-
tion of self-renewing ES cells could create a pool on
which to subsequently study differentiation without the
need for harvesting primary cells from tissue. They
were able to identify specific morphological changes in
the treated ES cells in response to treatment with differ-
ent peptides. Moreover, by looking at two different pro-
tein markers for differentiation, they could identify cells
undergoing changes to their cellular program on the mo-
lecular level. To launch this approach, the Kiessling
group developed array-patterning technology based
on cytophobic fluorinated alkane thiols and applied a
recently identified chemically defined culture medium
*Correspondence: lszewczak@cell.comto create fully controllable growth conditions. With an
eye to the future, Dr. Kiessling discussed the potential
for using this system to uncover specific differentiation
signals and their relevant cellular receptors.
Dr. Ann Valentine of Yale University discussed work
from her lab on titanium bioactivity. Eliciting periodic
chuckles from the audience, she wittily placed her
work in context by describing the challenges of securing
funding to investigate metal-based therapeutics, the
checkered history of titanium-based therapeutics like
titanocene dichloride, and the success of titanium-
based implants. A significant consequence of putting
titanium into the human body is that it winds up distrib-
uted throughout and associates with both chromatin
and specific proteins via an unknown mechanism.
Dr. Valentine opined that understanding the basic chem-
istry of titanium complexes in aqueous solutions may
provide insight into these observations. The major
mechanistic concern in cells is that the titanium ligands
hydrolyze, making the bioavailable species dramatically
different from the starting compound. For example, tita-
nocene’s two chloride ligands are known to exchange
with water within minutes of exposure to an aqueous
environment. Dr. Valentine described one of her lab’s
goals: the development of stable, water-soluble titanium
complexes. She went on to present results characteriz-
ing the stability of titanium citrate and ascorbate com-
plexes. Such complexes may allow more specific target-
ing of titanium to cancer cells, for example, which could
be cytotoxic. Moving to a more complicated system,
Dr. Valentine discussed the role of transferrin as a cellu-
lar metal-ion shuttle. Although principally responsible
for transporting iron into cells, transferrin binds tow40
metal ions, including titanium and the bismuth found in
PeptoBismol. Many tumors are known to require excess
iron, and consequently, have increased expression of
transferrin on their cells’ surfaces. Using an inorganic
model compound of transferrin and the protein itself,
work from her lab has defined the thermodynamic pa-
rameters for titanium binding. From this and the work
of others, she suggested that transferrin plays a key
role in the activity of titanium in vivo.
The symposium turned to nanoscience as Dr. Chad
Mirkin of Northwestern discussed challenges for the
future at the interface of biology, engineering, chemistry,
and materials science. He began by describing a remark-
able advance in Dip-Pen lithography to expand the scale
of the procedure. By increasing the number of pens
acting in parallel and aligned by gravity, workers in his
lab have been able to create an apparatus capable of
creating in excess of 50,000 copies of a single entity
(he showed a 2005 nickel at 80 nm resolution). Snazzy
tricks aside, Dr. Mirkin described many areas where
such technology could make a serious impact, includ-
ing X-ray crystallography, catalyst-development, and
whole-cell analyses. As one example, he presented a
study of a nanoarray of immobilized viral particles,
which retained full infectivity and, on the basis of a vari-
ety of genetic markers, were identical to unrestrained
particles. Such arrays might facilitate the study of viral
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DNA nanoparticle conjugates (100–200 copies of a DNA
on a 13 nm particle) that retain the recognition properties
of the constituent DNA sequences and their develop-
ment into molecular diagnostics. He began by laying
out an approach to achieve 10218-fold sensitivity in sin-
gle-mismatch detection and then moved on to explain
how the technology could serve as the underpinning
for ‘‘biological barcode’’ detection approach. His goal
is to create an ultrasensitive diagnostic system with
the ability to detect both nucleic acids and proteins.
The approach combines a magnetic bead decorated
with a specific antibody and the DNA-conjugated nano-
particle, magnetic separation of antibody-bound protein
(or nucleic acid) from a patient sample, subsequent re-
lease of the ‘‘barcode DNA,’’ and detection of the DNA
sequence (in amounts proportional to the isolated mac-
romolecule) with exquisite specificity. As an example, he
discussed the merits of identifying changes in prostate-
specific antigen (PSA) levels in postoperative men
where levels are currently below detection, or the need
for rigorous results to address the question of whether
PSA is a marker for breast cancer. Dr. Mirkin concluded
by highlighting the opportunities to develop the barcode
approach for identifying other biomarkers, as well as
small molecules and even metal ions.
After a break for lunch and a poster session, the sym-
posium continued with a talk by Dr. Ronald Raines from
the University of Wisconsin at Madison. He began by re-
acquainting the audience with the triple helix found in
collagen, formed from repeats of a triplet of amino acids,
and left the audience members looking at their arms
as he cited the statistic that collagen provides three-
quarters of the dry weight of skin. More surprisingly,
28% of the collagen repeats contain proline and 38%
hydroxyproline, an amino acid created via posttransla-
tional modification by a-ketoglutarate-dependent prolyl
4-hydroxylase, an iron-dependent enzyme. Prolyl hy-
droxylase activity is essential for C. elegans survival,
and in humans, loss of prolyl 4-hydroxylase activity
leads to scurvy. Conversely, overexpression of the en-
zyme produces fibrosis. Dr. Raines described the syn-
thesis of a-ketoglutarate analogs as inhibitors, and
experiments in worms to confirm their efficacy. Turning
to the modification itself, he described efforts from his
lab to investigate the functional role for the hydroxyl
group. To test an existing mechanistic mode that pro-
poses localization of two water molecules within each
collagen repeat via hydrogen bonding with the hy-
droxyls, he and his colleagues synthesized a 4-fluoro-
proline analog and characterized the biophysical prop-
erties of fluorine-modified triple helices. Fluorinated
helices had higher melting temperatures than either
prolyl- or hydroxyprolyl-containing ones. Stereochemi-
cally, fluorination in the native R configuration was criti-
cal to stability. Dr. Raines concluded by describing evi-
dence based on studies of the fluoro analog as well as
other proline derivatives for a significant stereoelec-
tronic contribution, fostered by hydroxyproline in the
native polymer, to the organization of the collagen-
peptide backbone, in contrast to the water-based heli-
cal stabilization model.
Yale University’s Benjamin Turk described the efforts
of his laboratory to develop a peptide-based inhibitorof anthrax lethal toxin. Lethal toxin, which persists after
antibiotic treatment of the infection, kills cellular macro-
phages via necrosis. It comprises two components, the
protective antigen involved in pore formation and lethal
factor (LF), a zinc-dependent metalloprotease. All six
known cellular targets for LF are MAP-kinase kinases
(MKKs). These kinases are the central enzymes in the
three-component phosphorylation cascades that trans-
duce a stimulus through a MKK-kinase, to the MKK, and
onto the MAP kinase (MAPK) that phosphorylates multi-
ple substrates, leading to a cellular response. LF cleaves
six of the seven MKKs, which removes the MAPK dock-
ing sites and turns signaling off. Dr. Turk’s lab used
a screening approach to uncover the substrate se-
quence preferences of the LF protease. They utilized
three screens to look for sequence determinants up-
stream and downstream of the cleavage site. Experi-
mental analyses revealed some selectivity for a hydro-
phobic amino acid and a proline in positions P10 and
P20, respectively (the first and second positions follow-
ing the cleavage site), and a preference for tyrosine at
P2 and one for basic residues at positions P4–P6 up-
stream of the cleavage site. Subsequent studies showed
that the consensus peptide derived from the screens
was a good substrate for LF, and it is now used in
small-molecule screens. Subsequently, the Turk group
tested a related substrate-based inhibitor bearing
a metal chelator at its C terminus and compared it to
a known, structurally similar, matrix metalloprotease
(MMP) inhibitor (also bearing a chelating group). The
MMP inhibitor was efficacious in an in vivo assay of lethal
toxin activity. Turk also commented on collaborative
structural analyses of LF bound separately to the pep-
tide substrate and to the MMP inhibitor, which revealed
that the tyrosine favored at P10 fit into a deep hydropho-
bic pocket with the rest of the peptide stretched across
the protein in an extended conformation. He concluded
by highlighting the lab’s ongoing work to determine
which of the MKKs is the critical target for LF.
Christopher Walsh of Harvard University Medical
School delivered the keynote address, closing the sym-
posium. Walsh began by introducing the audience to the
astonishing array of halogenated compounds produced
by natural biosynthetic pathways. The talk focused on
two enzyme classes that catalyze halogenation—flavin-
dependent enzymes and non-heme Fe(II) a-ketogluta-
rate-dependent enzymes. Mechanistically, the flavin-
dependent enzymes utilize FADH2 and oxygen to transfer
chlorine to electron-rich aromatic rings. As an example,
Walsh discussed studies of the overexpression of two
enzymes from the rebeccamycin gene cluster, RebH
and RebF, the former a flavin-dependent halogenase
and the latter a flavin reductase. In tandem, the ex-
pressed proteins catalyze the chlorination of trypto-
phan. Detailed mechanistic studies from his laboratory
suggested that the active chlorinating species is HOCl
or a chemical equivalent. Turning to halogenation by
non-heme Fe(II) a-ketoglutarate-dependent enzymes,
Walsh described two enzymes involved in syringomycin
synthesis, SyrB1 and SyrB2. SyrB1 is a nonribosomal
peptide synthase didomain protein containing A and T
domains. SyrB2 is a non-heme Fe(II) a-ketoglutarate-
dependent halogenase. Following anaerobic purifica-
tion, members of the Walsh group demonstrated that
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equivalent of iron. For halogenation of a SyrB1 bound
substrate, the enzyme is dependent on the a-ketogluta-
rate cofactor, oxygen, and iron. The Walsh and Drennan
labs (MIT) were able to show, using X-ray crystallogra-
phy, that the bound halogen (bromine was used in the
structure determination) replaced an expected carbox-
ylate ligand, derived from an Asp residue, in the iron co-
ordination sphere. Using the characteristic replacement
of an Asp conserved in non-heme Fe(II) a-ketoglutarate-
dependent oxygenases with Ala, the Walsh group iden-
tified other such halogenases. Dr. Walsh finished the ha-
logenation story with the discussion of other examples
of biological halogenation, including the barbamide
synthetic pathway and the mechanism for coronatine
biosynthesis.
